**Multiplex SARS-CoV-2 Genotyping PCR for Population-Level Variant Screening and Epidemiologic**

**Surveillance**

Hannah Wang, MD[a]*; Jacob A. Miller, MD[b]*; Michelle Verghese, BA[a]; Mamdouh Sibai, BS[c]; Daniel Solis,

BS[a]; Kenji O. Mfuh, PhD[c]; Becky Jiang, CLS[c]; Naomi Iwai, CLS[c]; Marilyn Mar, CLS[c]; ChunHong Huang,

MD[a]; Fumiko Yamamoto, MS[a]; Malaya K. Sahoo, PhD[a]; James Zehnder, MD[a]; Benjamin A. Pinsky, MD,

PhD[a,c,d]#

[a] Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA

[b] Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA

[c] Clinical Virology Laboratory, Stanford Health Care, Stanford, CA, USA

[d] Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University

School of Medicine, Stanford, CA, USA

Running Head: SARS-CoV-2 Variant Genotyping PCR

#Address correspondence to Benjamin A. Pinsky, MD, PhD, bpinsky@stanford.edu

*Authors Hannah Wang and Jacob A. Miller contributed equally to this work.

**ABSTRACT:**

Emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with concerning

phenotypic mutations is of public health interest. Genomic surveillance is an important tool for pandemic

response, but many laboratories do not have the resources to support population-level sequencing. We

hypothesized that a spike genotyping nucleic acid amplification test (NAAT) could facilitate high-

throughput variant surveillance.

We designed and analytically validated a one-step multiplex allele-specific reverse transcriptase

polymerase chain reaction (RT-qPCR) to detect three non-synonymous spike protein mutations (L452R,

E484K, N501Y). Assay specificity was validated with next-generation whole-genome sequencing. We

then screened a large cohort of SARS-CoV-2 positive specimens from our San Francisco Bay Area

population.

Between December 1, 2020 and March 1, 2021, we screened 4,049 unique infections by genotyping RT-

qPCR, with an assay failure rate of 2.8%. We detected 1,567 L452R mutations (38.7%), 34 N501Y

mutations (0.84%), 22 E484K mutations (0.54%), and 3 (0.07%) E484K+N501Y mutations. The assay

had near-perfect (98-100%) concordance with whole-genome sequencing in a validation subset of 229

specimens, and detected B.1.1.7, B.1.351, B.1.427, B.1.429, B.1.526, and P.2 variants, among others.

The assay revealed rapid emergence of L452R in our population, with a prevalence of 24.8% in

December 2020 that increased to 62.5% in March 2021.

We developed and clinically implemented a genotyping RT-qPCR to conduct high-throughput SARS-CoV-

2 variant screening. This approach can be adapted for emerging mutations and immediately implemented

in laboratories already performing NAAT worldwide using existing equipment, personnel, and extracted

nucleic acid.

**INTRODUCTION**

High transmission rates during the coronavirus disease 2019 (COVID-19) pandemic have facilitated the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. The underlying genomic diversity defining these variants is indicative of natural selection of mutations with phenotypic significance.(1–3) In particular, variants associated with increased transmission, virulence, or resistance to host, vaccine, or antiviral immunity are of significant public health concern.(4–17) Other mutations could also potentially impact diagnostic sensitivity.(18) Genomic surveillance that is representative of the newly-infected population is therefore an important tool for pandemic response.

As of March 2021, the United States Centers for Disease Control and Prevention (CDC), European Centre for Disease Prevention and Control (ECDC), and World Health Organization (WHO) identified multiple SARS-CoV-2 lineages as variants of concern or variants of interest (VOC/VOI).(19–21) Many share the spike protein mutations E484K (B.1.351, B.1.525, B.1.526, P.1, P.2), N501Y (B.1.1.7, B.1.351, P.1), and/or L452R (B.1.427, B.1.429), among others. Such variants have primarily been identified by targeted or whole-genome sequencing. However, due to the required resources, technical expertise, and equipment for sequencing, few public health systems have successfully coordinated timely large-scale sequencing efforts. Among individual institutions that have developed sequencing programs, there is tremendous variability in throughput, selection criteria, and methodology that confound accurate estimates of individual variant prevalence. Because the vast majority of laboratories worldwide do not have the resources required to develop and support large-scale sequencing initiatives, a complementary surveillance strategy is desirable.

Upper respiratory nucleic acid amplification tests (NAATs) are the mainstay of SARS-CoV-2 diagnosis. In contrast to sequencing, nearly all laboratories offering NAATs have equipment and trained personnel for nucleic acid extraction and real-time polymerase chain reaction. We therefore aimed to develop a highly-accessible spike genotyping NAAT for high-throughput and rapid screening of positive SARS-CoV-2 samples. We hypothesized that this assay would facilitate large-scale VOC/VOI screening and track

emergence of mutations in our population. This approach enables population-based triaging of samples

to centers performing sequencing analysis for lineage determination and increases access to variant

surveillance.

**MATERIALS AND METHODS**

*Assay Design*

In January 2021, the B.1.1.7, B.1.351, B.1.1.28 descendant P.1, B.1.1.28 descendant P.2, and

B.1.427/B.1.429 variant lineages were of primary global and local epidemiologic significance. Informed by

recent studies describing mutation phenotypic significance and convergent evolution, we elected to begin

screening our population for the spike N501Y (B.1.1.7, B.1.351, P.1), E484K (B.1.351, P.1, P.2), and

L452R (B.1.427/B.1.429) mutations.

We therefore designed a one-step multiplex allele-specific reverse transcriptase quantitative polymerase

chain reaction (RT-qPCR) to detect these three non-synonymous single nucleotide variants in the spike

gene (N501Y: RefSeq NC_045512 23063A>T; E484K: 23012G>A, L452R: 22917 T>G). We selected the

wild-type N501 allele (23063A) to serve as a control for those samples that lack any of the targeted

mutations.

To permit single reaction multiplexing, we designed primer sets and dual-labeled hydrolysis probes to

maximize each probe's mismatch-ΔTm while maintaining probe specificity and a sufficiently high

annealing temperature (Table S1). This 2-7°C decrease in each probe's annealing temperature (ΔTm)

when binding SARS-CoV-2 cDNA with a single nucleotide mismatch distinguishes mutant from wild-type

nucleic acid templates. Given the proximity between the E484K and N501Y mutations, two primer sets

(flanking L452R and E484K/N501Y, respectively) were designed with annealing temperatures similar to

or above probe annealing temperatures.

Recognizing the potential for mutations in the targets, on January 26, 2021 we downloaded all available

SARS-CoV-2 sequences from GISAID annotated as B.1.1.7 (n=7,864), B.1.351 (n=341), or

B.1.427/B.1.429 variants (n=622), as well as all available sequences from NCBI collected prior to

December 2020 (n=31,016).(22) Primer sequences were conserved in >98.8% of all sequences; mutant

probe sequences were conserved in >99.7% of variant-specific sequences and were present in only 0.1%

of pre-December 2020 NCBI sequences. The wild-type N501 probe sequence was conserved in 99.2% of

pre-December 2020 NCBI sequences.

Additional details regarding synthetic controls, oligonucleotides, cycling conditions, fluorescence

thresholds, analytical validation, and assay interpretation for reporting are provided in the Supplemental

Methods, Tables S1-S6, and Fig. S1.

*Clinical Specimens*

This study included upper respiratory swab specimens collected between December 1, 2020 and March

3, 2021 from patients as part of routine clinical care. All specimens testing positive for SARS-CoV-2 by

NAAT with RT-qPCR $C_t \leq 30$ or transcription-mediated amplification relative light units (RLU) ≥ 1,100

during this period were subject to multiplex allele-specific genotyping RT-qPCR. All tests were conducted

at the Stanford Clinical Virology Laboratory, which serves tertiary-care academic hospitals and affiliated

outpatient facilities in the San Francisco Bay Area. After development and analytical validation of our

genotyping RT-qPCR, we retrospectively screened all eligible positive specimens dating back to

December 1, 2020, and then began prospective genotyping on February 19, 2021. This study was

conducted with Stanford institutional review board approval (protocol 48973), and individual consent was

waived.

Prior to genotyping RT-qPCR, initial respiratory SARS-CoV-2 NAAT was conducted on a variety of

platforms (Table 1, Supplemental Methods).(23–25) All assays were conducted according to

manufacturer and emergency authorization instructions.(26, 27)

*Assay Validation with Next-Generation Sequencing*

A subset of wild-type and mutant specimens genotyped by RT-qPCR were confirmed by WGS in a

validation dataset. We adapted an existing WGS pipeline for poliovirus genotyping to conduct SARS-

CoV-2 whole-genome amplicon-based sequencing (Supplemental Methods).(28–30) Pangolin was used

for PANGO lineage assignment, while Nextclade v0.14.2 and auspice.us 0.5.0. were used to assign

Nextstrain clades and perform phylogenetic placement.(2, 30, 31) PANGO lineage names and Nextstrain

clade names were assigned as of April 5, 2021.

*Statistical Analysis*

Baseline continuous data were compared with t-tests or Wilcoxon rank-sum tests, whereas categorical

data were compared with Fisher exact tests. Positive percent agreement (PPA) and negative percent

agreement (NPA) were reported with Clopper-Pearson score 95% binomial confidence intervals using

next-generation sequencing as the reference method. Analyses were conducted using the R statistical

software package. This study was reported in accordance with STARD guidelines.(32)

**RESULTS**

*Population-Level Screening*

During the period between December 1, 2020 and March 3, 2021, our clinical virology laboratory reported

165,501 negative and 13,083 positive SARS-CoV-2 NAATs among 119,154 unique patients. These

13,083 positive NAATs corresponded to 11,635 patients (Table 1). We assumed this reflected

approximately 11,635 unique infections, presuming no re-infection during the study period.

After triaging specimens with higher viral load and sufficient remaining material, we screened 4,049

specimens from unique patients by genotyping RT-qPCR (Table 1, Fig. 1). Amplification curves from RT-

qPCR were interpreted according to Table S4, with example cases presented in Fig. S2. A total of 174

specimens had amplification failure on initial RT-qPCR, either due to low viral load, amplification failure,

or reaction setup error. Among these specimens, 59 were successfully genotyped on repeat RT-qPCR

and are included in the analysis dataset, while the remaining 115 were unable to genotype,

corresponding to an assay failure rate of 2.8%. Among initial diagnostic specimens tested by RT-qPCR

with available $C_t$ values (3,142), median viral load was significantly lower among samples unable to

genotype ($C_t$ 28.8 vs 18.8, $p$<0.001).

Among the 3,934 genotyped specimens, we identified 1,567 (38.7%) with isolated L452R mutations, 34

(0.84%) with isolated N501Y mutations, 22 (0.54%) with isolated E484K mutations, and 3 (0.07%) with

E484K+N501Y mutations.

*Assay Validation with Next-Generation Sequencing*

In addition to validating the assay's analytical performance (Tables S5-S6), we assessed clinical positive

(PPA) and negative percent agreement (NPA) of genotyping RT-qPCR using WGS as a reference

method. Among 229 specimens from unique patients assessed by both RT-qPCR and WGS (Table 1),

PPA of RT-qPCR for L452R, E484K, and N501Y were: 100% (95% CI 95-100%), 100% (95% CI 80-

100%), and 100% (95% CI 86-100%), respectively (Table 2). There were no false negatives by RT-qPCR

for L452R, E484K, or N501Y. Furthermore, there were no false positives for E484K (NPA: 100%, 95% CI

98-100%) or N501Y (NPA: 100%, 95% CI 98-100%).

There were three specimens positive for L452R by RT-qPCR but negative for by WGS (NPA: 98%, 95%

CI 95-99%). These had L452R $C_t$ values of 20.0, 22.8, and 31.2 with appropriate amplification curves and

appropriate N501 wild-type (Cy3.5) internal control amplification ($C_t$ 21.0, 18.4, 30.0). Sequencing

coverage and codon calls at the L452 loci were 1,890/1,907 (99%), 2,407/2,424 (99%), and 2,817/2,841

(99%) for these three specimens, which were assigned lineages of B.1.1.222, B.1.2, and B.1.243,

respectively. All three specimens were re-extracted and repeated by RT-qPCR with the same result.

Among the 229 specimens tested by both RT-qPCR and WGS, the distribution of PANGO lineages is

presented in Table 3, and a phylogenetic tree of Nextstrain clades is presented in Fig. 2. The 120

specimens which were wild-type by RT-qPCR were most commonly assigned lineages of B.1.2 (34%)

and B.1 (12%). Among the 70 specimens with isolated L452 mutations by RT-qPCR, 43 (60%) and 23

(33%) were B.1.427 and B.1.429, respectively. Among the 22 specimens with isolated N501Y mutations

by RT-qPCR, 17 (77%) were B.1.1.7. Among the 14 specimens with isolated E484K mutations by RT-

qPCR, 11 (79%) were P.2, 2 (14%) were B.1, and 1 (7%) was B.1.526 (Fig. 3). The three specimens with

E484K+N501Y mutations were all of B.1.351 lineage. Sequencing quality measures and GISAID

accessions are provided in Tables S7-S8.

*Epidemiologic Emergence of L452R*

During the study period, we observed rapid emergence of the L452R mutation in our population (Fig. 4,

Table 4). The majority of such specimens assessed by WGS were B.1.427/B.1.429 variants (93%).

Although the number of new infections in our population decreased between January and March 2021,

the proportion of new infections harboring the L452R mutation increased from 24.8% in December 2020

to 62.5% in March 2021.

**DISCUSSION**

Rapid, accessible, and high-throughput epidemiologic surveillance for SARS-CoV-2 variants is of public

health interest. We describe a one-step multiplex RT-qPCR assay that facilitated screening of

approximately 4,000 unique infections during a period of high transmission in the San Francisco Bay

Area. This assay had excellent concordance with WGS and revealed rapid emergence of variants

harboring L452R. In contrast to WGS, the widely-available equipment, resources, and trained personnel

make this RT-qPCR assay accessible to nearly all laboratories already offering SARS-CoV-2 NAATs. All

current CDC-classified variants of concern (B.1.1.7, P.1, B.1.351, B.1.427, B.1.429) and most variants of

interest (P.2, B.1.525, some but not all B.1.526) harbor at least one of the L452R, E484K, or N501Y spike

protein mutations, enabling population-level triaging by RT-qPCR to centers performing WGS for lineage

determination. This approach has implications for outbreak surveillance, diagnostic testing,

transmissibility, virulence, and vaccine and/or antiviral efficacy.

The CDC, ECDC, and WHO have identified multiple SARS-CoV-2 lineages as variants of concern (VOC)

or variants of interest (VOI).(19–21) Many of these variants share the E484K mutation (B.1.351, B.1.525,

some B.1.526, P.1, P.2), N501Y mutation (B.1.1.7, B.1.351, P.1), and/or the L452R mutation (B.1.427,

B.1.429). Previously-reported studies guided by large-scale genomic surveillance have suggested

increased transmissibility, virulence, or reduced vaccine/antiviral efficacy/neutralization corresponding to

the phenotypic significance of these spike protein mutations.(4–17) Moreover, mutations in the spike

gene (*S* gene) may lead to false negative NAAT results.(18)

While whole-genome sequencing is required to confirm infection with a specific variant, not all centers

have the required resources or personnel to conduct large-scale variant genotyping on a high proportion

of incident cases. Allele-specific NAAT-based methods are an alternative to large-scale sequencing

programs, but few methods have been described. Korukluoglu et al. recently described a one-step RT-

qPCR assay to detect the N501Y and HVdel69-70 using allele-specific forward primers, reserving

ORF1ab as an internal control.(33) This assay is conducted in two separate reactions, with the first

targeting N501, ORF1ab, and HV69-70del, while the second amplifies N501Y, ORF1ab, and HV69-70del.

The authors described high concordance (100%) with Sanger and next-generation sequencing. A

disadvantage of this method is the absence of screening for E484K and the requirement for two separate

reactions. More recently, Banada et al. reported an RT-qPCR method for detection of N501Y using melt

curve analysis.(34) This assay includes allele-specific molecular beacon probes for N501 and N501Y

conjugated to different fluorophores, similar to our assay. Twenty patient specimens were tested and a

subset were confirmed by Sanger sequencing.

Vogels et al. have also described an RT-qPCR assay to detect the ORF1ab 3675-3677 and spike HV69-

70 deletions.(35) The deletions are detected via ORT1ab-Cy5 and spike-HEX probe dropout, reserving

the CDC N1 primer/probe set as an internal control. This assay was concordant with 76 sequenced

specimens. Limitations of this assay, as described by the authors, are N1-FAM autofluorescence leading

to false B.1.1.7 drop-out and absence of the ORF1ab 3675-3677 deletion in select B.1.351 isolates. While

these deletions are surrogates for B.1.1.7, B.1.351, and P.1, screening for N501Y and E484K may be

more specific to variants of concern/interest and appear to be causally-associated with concerning

phenotypes. Another genotyping NAAT utilized a two-step approach combining the CDC-based

laboratory-developed RT-qPCR and the ThermoFisher TaqPath COVID-19 RT-PCR.(36) With the intent

to identify B.1.1.7 variants, the authors screened 1,035 samples for TaqPath *S* gene dropout and

genotyped two specimens by multiplex droplet digital PCR amplifying HV69-70del, N501Y, del145, and

S982A in two reactions, which were positive for these four mutations. Next-generation sequencing

confirmed B.1.1.7 lineage. Limitations of this genotyping approach include dependence upon *S* gene

dropout followed by more labor-intensive ddPCR.

The largest NAAT-based genotyping series thus far was a national effort in France recently reported by

Haim-Boukobza et al.(37) The authors used two separate assays to screen for the HVdel69-70 and

N501Y mutations in 35,208 samples, with an uninterpretable assay rate of 19.0% and sequencing

concordance Kappa coefficient of 0.87-0.88.

To our knowledge, the present study is the largest NAAT-based SARS-CoV-2 genotyping initiative in the

United States. While large multi-institutional programs such as the United Kingdom COVID-19 genomics

consortium have sequenced more than 250,000 specimens, many public health systems or private

institutions are unable to conduct high-throughput genotyping due to the required cost, equipment, and

expertise. The RT-qPCR assay we describe is accessible to any laboratory conducting RT-qPCR SARS-

CoV-2 testing, and shares much of the same equipment and reagents. Specimens positive for SARS-

CoV-2 by initial NAAT can be rapidly genotyped within hours using the same extracted nucleic acid, and

the cost of this assay's custom oligonucleotides are less than one U.S. Dollar per reaction. As proof of

concept, we have validated this assay on various qPCR instruments and master mixes, demonstrating

that individual laboratories may adapt this assay to existing NAAT workflows.

As evidence of the feasibility of high-throughput testing, we rapidly implemented reflex genotyping RT-

qPCR for positive specimens and screened more than 4,000 infections, thereby facilitating local

surveillance of L452R mutation emergence. Our results are consistent with a large-scale whole-genome

sequencing initiative of 2,172 specimens from 44 counties in California.(12) This series suggested a 19-

24% increase in transmissibility relative to wild-type circulating strains, and was the basis for L452R

surveillance in our study. Due to the local prevalence of circulating L452R mutations, our screening

initiative identified approximately 1,500 unique infections harboring L452R mutations.

This assay has several limitations. Sporadic isolated L452R, E484K, and N501Y mutations are well-

described and are not necessarily indicative of VOC/VOI. For example, in our series of 229 sequenced

specimens genotyped by RT-qPCR, isolated E484K or N501Y mutations by PCR were VOC/VOI in 86%

and 77% of cases, respectively, while the remaining were uncommon variants. Although our assay does

not screen for several other mutations of interest (HVdel69-70, K417N, P681H, Y453F), it is

advantageous that such variants are screen-detected via N501Y (B.1.1.7: del69-70, P681H), E484K (P.1

and B.1.351: K417N), and/or L452R. An additional limitation is the lack of wild-type probes for L452 and

E484. Although this choice was intentional to maximize efficiency, it introduces the possibility that

synonymous or alternate non-synonymous mutations (e.g. E484Q) within the probe binding site could

lead to an erroneous result. Lastly, variants may develop new mutations in primer and/or probe sites,

potentially leading to false negatives. As such, these primer/probe sequences should be regularly

checked against all available GISAID sequences, and new VOC/VOI should be monitored for potential

assay interference. An additional limitation is exclusion of samples with lower viral load in an effort to

successfully genotype. Although our assay failure rate was low (2.8%), analytical sensitivity could be

improved by increasing template volume. Although the present series of 4,049 infections is a subset of

the 11,635 unique consecutive infections between December 2020 and March 2021, the genotyped

population was similar to the overall population (Table 1). Nevertheless, our results may not be

necessarily generalizable to all new infections.

We developed and rapidly implemented a one-step multiplex allele-specific RT-qPCR assay to conduct

rapid and high-throughput SARS-CoV-2 variant screening in the San Francisco Bay Area. The assay had

near-perfect concordance with whole-genome next-generation sequencing and facilitates detection of all

common and uncommon variants of concern/interest harboring the L452R, E484K, or N501Y mutations.

This approach can be adapted for emerging mutations and implemented in laboratories already

conducting SARS-CoV-2 NAAT using existing resources and extracted nucleic acid.

**ACKNOWLEDGEMENTS**

We sincerely thank the Stanford Clinical Virology Laboratory staff for their dedication and commitment to

patient care in the face of unprecedented challenges presented by the COVID-19 pandemic. We also

thank the Stanford Protein and Nucleic Acid Facility for oligonucleotide synthesis.

**FUNDING/CONFLICTS OF INTEREST**

This study was not funded by any grants, scholarships, fellowships, or commercial entities. The authors

report no conflicts of interest related to this work.

**REFERENCES**

1.  Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, Hengartner N, Giorgi EE, Bhattacharya T, Foley B, Hastie KM, Parker MD, Partridge DG, Evans CM, Freeman TM, de Silva TI, Sheffield COVID-19 Genomics Group, McDanal C, Perez LG, Tang H, Moon-Walker A, Whelan SP, LaBranche CC, Saphire EO, Montefiori DC. 2020. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell 182:812-827.e19.

2.  Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, Sagulenko P, Bedford T, Neher RA. 2018. Nextstrain: real-time tracking of pathogen evolution. Bioinforma Oxf Engl 34:4121–4123.

3.  Day T, Gandon S, Lion S, Otto SP. 2020. On the evolutionary epidemiology of SARS-CoV-2. Curr Biol 30:R849–R857.

4.  Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, Pearson CAB, Russell TW, Tully DC, Washburne AD, Wenseleers T, Gimma A, Waites W, Wong KLM, van Zandvoort K, Silverman JD, CMMID COVID-19 Working Group, COVID-19 Genomics UK (COG-UK) Consortium, Diaz-Ordaz K, Keogh R, Eggo RM, Funk S, Jit M, Atkins KE, Edmunds WJ. 2021. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science https://doi.org/10.1126/science.abg3055.

5.  Galloway SE. 2021. Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–January 12, 2021. MMWR Morb Mortal Wkly Rep 70.

6.  Muik A, Wallisch A-K, Sänger B, Swanson KA, Mühl J, Chen W, Cai H, Maurus D, Sarkar R, Türeci Ö, Dormitzer PR, Şahin U. 2021. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science 371:1152–1153.

7.   Densely sampled viral trajectories suggest longer duration of acute infection with B.1.1.7 variant relative to non-B.1.1.7 SARS-CoV-2 | medRxiv.

8.    Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, Hinsley WR, Laydon DJ, Dabrera

G, O'Toole Á, Amato R, Ragonnet-Cronin M, Harrison I, Jackson B, Ariani CV, Boyd O, Loman NJ,

McCrone JT, Gonçalves S, Jorgensen D, Myers R, Hill V, Jackson DK, Gaythorpe K, Groves N,

Sillitoe J, Kwiatkowski DP, Consortium TC-19 GU (COG-U, Flaxman S, Ratmann O, Bhatt S,

Hopkins S, Gandy A, Rambaut A, Ferguson NM. 2021. Transmission of SARS-CoV-2 Lineage

B.1.1.7 in England: Insights from linking epidemiological and genetic data. medRxiv

2020.12.30.20249034.

9.    Resende PC, Gräf T, Paixão ACD, Appolinario L, Lopes RS, Mendonça AC da F, Rocha ASB da,

Motta FC, Neto LGL, Khouri R, Oliveira CI de, Santos-Muccillo P, Bezerra JF, Teixeira DLF,

Riediger I, Debur M do C, Ribeiro-Rodrigues R, Leite AB, Santos CA do, Gregianini TS, Fernandes

SB, Bernardes AFL, Cavalcanti AC, Miyajima F, Sachhi C, Mattos T, Costa CF da, Delatorre E,

Wallau GL, Naveca FG, Bello G, Siqueira MM, Network  on behalf of FC-19 GS. 2021. A potential

SARS-CoV-2 variant of interest (VOI) harboring mutation E484K in the Spike protein was identified

within lineage B.1.1.33 circulating in Brazil. bioRxiv 2021.03.12.434969.

10.   Xie X, Liu Y, Liu J, Zhang X, Zou J, Fontes-Garfias CR, Xia H, Swanson KA, Cutler M, Cooper D,

Menachery VD, Weaver SC, Dormitzer PR, Shi P-Y. 2021. Neutralization of SARS-CoV-2 spike

69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat Med

https://doi.org/10.1038/s41591-021-01270-4.

11.    2021. Phylogenetic relationship of SARS-CoV-2 sequences from Amazonas with emerging

Brazilian variants harboring mutations E484K and N501Y in the Spike protein - SARS-CoV-2

coronavirus / nCoV-2019 Genomic Epidemiology. Virological.

12.   Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, Sotomayor-González A,

Glasner DR, Reyes KR, Gliwa AS, Reddy NP, Martin CSS, Federman S, Cheng J, Balcerek J,

Taylor J, Streithorst JA, Miller S, Kumar GR, Sreekumar B, Chen P-Y, Schulze-Gahmen U, Taha

TY, Hayashi J, Simoneau CR, McMahon S, Lidsky PV, Xiao Y, Hemarajata P, Green NM, Espinosa

A, Kath C, Haw M, Bell J, Hacker JK, Hanson C, Wadford DA, Anaya C, Ferguson D, Lareau LF,

Frankino PA, Shivram H, Wyman SK, Ott M, Andino R, Chiu CY. 2021. Transmission, infectivity,

and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R

spike protein mutation. medRxiv 2021.03.07.21252647.

13.  Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, Padayachee SD, Dheda K,

Barnabas SL, Bhorat QE, Briner C, Kwatra G, NGS-SA, Team W-VC, Ahmed K, Aley P, Bhikha S,

Bhiman JN, Bhorat AE, Plessis J du, Esmail A, Groenewald M, Horne E, Hwa S-H, Jose A, Lambe

T, Laubscher M, Malahleha M, Masenya M, Masilela M, McKenzie S, Molapo K, Moultrie A, Oelofse

S, Patel F, Pillay S, Rhead S, Rodel H, Rossouw L, Taoushanis C, Tegally H, Thombrayil A, Eck S

van, Wibmer CK, Durham NM, Kelly EJ, Villafana TL, Gilbert S, Pollard AJ, Oliveira T de, Moore PL,

Sigal A, Izu A. 2021. Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine

against the B.1.351 variant in South Africa. medRxiv 2021.02.10.21251247.

14.  Wang P, Wang M, Yu J, Cerutti G, Nair MS, Huang Y, Kwong PD, Shapiro L, Ho DD. 2021.

Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization. bioRxiv

2021.03.01.433466.

15.  Emary KRW, Golubchik T, Aley PK, Ariani CV, Angus BJ, Bibi S, Blane B, Bonsall D, Cicconi P,

Charlton S, Clutterbuck E, Collins AM, Cox T, Darton T, Dold C, Douglas AD, Duncan CJA, Ewer K,

Flaxman A, Faust SN, Ferreira DM, Feng S, Finn A, Folegatti PM, Fuskova M, Galiza E, Goodman

AL, Green CM, Green CA, Greenland M, Hallis B, Heath PT, Hay J, Hill HC, Jenkin D, Kerridge S,

Lazarus R, Libri V, Lillie PJ, Ludden C, Marchevsky NG, Minassian AM, McGregor AC, Farooq

Mujadidi Y, Phillips DJ, Plested E, Pollock KM, Robinson H, Smith A, Song R, Snape MD,

Sutherland RK, Thomson EC, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Williams CJ, Hill

AVS, Lambe T, Gilbert SC, Voysey M, Ramasamy MN, Pollard A, Consortium C-19 GU (COG-U,

Group OCVT. 2021. Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC

202012/01 (B.1.1.7). ID 3779160. SSRN Scholarly Paper, Social Science Research Network,

Rochester, NY.

16.    Collier DA, Marco AD, Ferreira IATM, Meng B, Datir R, Walls AC, S SAK, Bassi J, Pinto D, Fregni

CS, Bianchi S, Tortorici MA, Bowen J, Culap K, Jaconi S, Cameroni E, Snell G, Pizzuto MS,

Pellanda AF, Garzoni C, Riva A, Collaboration TC-NBC-19, Elmer A, Kingston N, Graves B, McCoy

LE, Smith KG, Bradley JR, Temperton N, L LC-G, Barcenas-Morales G, Consortium TC-19 GU

(COG-U, Harvey W, Virgin HW, Lanzavecchia A, Piccoli L, Doffinger R, Wills M, Veesler D, Corti D,

Gupta RK. 2021. SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and

monoclonal antibodies. medRxiv 2021.01.19.21249840.

17.    Shen X, Tang H, McDanal C, Wagh K, Fischer W, Theiler J, Yoon H, Li D, Haynes BF, Sanders KO,

Gnanakaran S, Hengartner N, Pajon R, Smith G, Dubovsky F, Glenn GM, Korber B, Montefiori DC.

2021. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral

Spike vaccines. bioRxiv 2021.01.27.428516.

18.    Health C for D and R. 2021. Genetic Variants of SARS-CoV-2 May Lead to False Negative Results

with Molecular Tests for Detection of SARS-CoV-2 - Letter to Clinical Laboratory Staff and Health

Care Providers. FDA.

19.    CDC. 2020. Cases, Data, and Surveillance. Cent Dis Control Prev.

20.    2021. Risk assessment: SARS-CoV-2 - increased circulation of variants of concern and vaccine

rollout in the EU/EEA, 14th update. Eur Cent Dis Prev Control.

21.    Weekly epidemiological update on COVID-19 - 30 March 2021.

22.    Elbe S, Buckland-Merrett G. 2017. Data, disease and diplomacy: GISAID's innovative contribution

to global health. Glob Chall Hoboken NJ 1:33–46.

23.    Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink S, Schneider

J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink S, Wijsman L, Goderski

G, Romette J-L, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C, Koopmans MP, Drosten C.

2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance 25.

24.   Bulterys PL, Garamani N, Stevens B, Sahoo MK, Huang C, Hogan CA, Zehnder J, Pinsky BA. 2020.

Comparison of a laboratory-developed test targeting the envelope gene with three nucleic acid

amplification tests for detection of SARS-CoV-2. J Clin Virol Off Publ Pan Am Soc Clin Virol

129:104427.

25.   Hogan CA, Sahoo MK, Pinsky BA. 2020. Sample Pooling as a Strategy to Detect Community

Transmission of SARS-CoV-2. JAMA 323:1967–1969.

26.    In Vitro Diagnostics EUAs - Molecular Diagnostic Tests for SARS-CoV-2 | FDA.

27.    Stanford Health Care Clinical Virology Laboratory. Food and Drug Administration Emergency Use

Authorization: SARS-CoV-2 RT-PCR Assay.

28.   Sahoo MK, Holubar M, Huang C, Mohamed-Hadley A, Liu Y, Waggoner JJ, Troy SB, Garcia-Garcia

L, Ferreyra-Reyes L, Maldonado Y, Pinsky BA. 2017. Detection of Emerging Vaccine-Related

Polioviruses by Deep Sequencing. J Clin Microbiol 55:2162–2171.

29.   Quick J, Grubaugh ND, Pullan ST, Claro IM, Smith AD, Gangavarapu K, Oliveira G, Robles-

Sikisaka R, Rogers TF, Beutler NA, Burton DR, Lewis-Ximenez LL, de Jesus JG, Giovanetti M, Hill

SC, Black A, Bedford T, Carroll MW, Nunes M, Alcantara LC, Sabino EC, Baylis SA, Faria NR,

Loose M, Simpson JT, Pybus OG, Andersen KG, Loman NJ. 2017. Multiplex PCR method for

MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples. 6.

Nat Protoc 12:1261–1276.

30.   Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, du Plessis L, Pybus OG. 2020. A

dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. 11. Nat

Microbiol 5:1403–1407.

31.   Sagulenko P, Puller V, Neher RA. 2018. TreeTime: Maximum-likelihood phylodynamic analysis.

Virus Evol 4.

32.    Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, Lijmer JG, Moher D,

Rennie D, de Vet HCW, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen

JF, STARD Group. 2015. STARD 2015: An Updated List of Essential Items for Reporting Diagnostic

Accuracy Studies. Radiology 277:826–832.

33.    Korukluoglu G, Kolukirik M, Bayrakdar F, Ozgumus GG, Altas AB, Cosgun Y, Ketre Kolukirik CZ.

2021. 40 minutes RT-qPCR Assay for Screening Spike N501Y and HV69-70del Mutations. preprint,

Microbiology.

34.    Banada P, Green R, Banik S, Chopoorian A, Streck D, Jones R, Chakravorty S, Alland D. 2021. A

Simple RT-PCR Melting temperature Assay to Rapidly Screen for Widely Circulating SARS-CoV-2

Variants. MedRxiv Prepr Serv Health Sci https://doi.org/10.1101/2021.03.05.21252709.

35.    Vogels CBF, Breban MI, Alpert T, Petrone ME, Watkins AE, Ott IM, de Jesus JG, Claro IM,

Magalhães Ferreira G, Crispim MAE, Brazil-UK CADDE Genomic Network, Singh L, Tegally H,

Anyaneji UJ, NGS-SA, Hodcroft EB, Mason CE, Khullar G, Metti J, Dudley JT, MacKay MJ, Nash M,

Wang J, Liu C, Hui P, Murphy S, Neal C, Laszlo E, Landry ML, Muyombwe A, Downing R, Razeq J,

de Oliveira T, Faria NR, Sabino EC, Neher RA, Fauver JR, Grubaugh ND. 2021. PCR assay to

enhance global surveillance for SARS-CoV-2 variants of concern. preprint, Infectious Diseases

(except HIV/AIDS).

36.    Perchetti GA, Zhu H, Mills MG, Shrestha L, Wagner C, Bakhash SM, Lin M, Xie H, Huang M-L,

Mathias P, Bedford T, Jerome KR, Greninger AL, Roychoudhury P. 2021. Specific allelic

discrimination of N501Y and other SARS-CoV-2 mutations by ddPCR detects B.1.1.7 lineage in

Washington State. medRxiv 2021.03.10.21253321.

37.    Haim-Boukobza S, Roquebert B, Trombert-Paolantoni S, Lecorche E, Verdurme L, Foulongne V,

Selinger C, Michalakis Y, Sofonea MT, Alizon S. Early Release - Detecting Rapid Spread of SARS-

CoV-2 Variants, France, January 26–February 16, 2021 - Volume 27, Number 5—May 2021 -

Emerging Infectious Diseases journal - CDC https://doi.org/10.3201/eid2705.210397.

**TABLES**

**Table 1.** Patient Characteristics and Aggregate Genotyping RT-qPCR Screening Results During Study Period

| Characteristic | All SARS-CoV-2 Infections | RT-qPCR Population | WGS Validation Subset |
|---|---|---|---|
| Patients | 11,636 | 4,049 | 229 |
| Age at First Positive NAAT | 36 [23-52] | 37 [23-53] | 37 [23-52] |
| Female | 6,009 (51.64%) | 2,065 (51.00%) | 128 (55.90%) |
| Initial Diagnostic Specimen | - | - | - |
|   Month of Diagnosis | - | - | - |
|     December 2020 | 6,074 (52.20%) | 344 (8.50%) | 18 (7.86%) |
|     January 2021 | 4,381 (37.65%) | 3,050 (75.33%) | 170 (74.24%) |
|     February 2021 | 1,119 (9.62%) | 640 (15.80%) | 37 (16.16%) |
|     March 2021 | 62 (0.53%) | 15 (0.37%) | 4 (1.75%) |
|   Specimen Collection Site | - | - | - |
|     Outpatient COVID-19 Screening Site | 6,187 (53.18%) | 2,393 (59.10%) | 138 (60.26%) |
|     Emergency Department | 2,633 (22.62%) | 704 (17.39%) | 34 (14.85%) |
|     Outpatient Laboratory | 1,190 (10.23%) | 469 (11.58%) | 24 (10.48%) |
|     Occupational Health | 628 (5.40%) | 123 (3.04%) | 6 (2.62%) |
|     Outpatient Clinic | 564 (4.85%) | 210 (5.19%) | 20 (8.73%) |
|     Urgent Care | 220 (1.89%) | 75 (1.85%) | 6 (2.62%) |
|     Inpatient Floor | 154 (1.32%) | 55 (1.36%) | 1 (0.43%) |
|     Perioperative/Periprocedural | 28 (0.24%) | 11 (0.27%) | 0 (0.00%) |
|     Intensive Care Unit | 20 (0.17%) | 4 (0.10%) | 0 (0.00%) |
|     Infusion Center | 10 (0.09%) | 3 (0.07%) | 0 (0.00%) |
|     Home Healthcare | 2 (0.02%) | 2 (0.05%) | 0 (0.00%) |
|   Specimen Source | - | - | - |
|     Nasopharyngeal Swab | 6,607 (56.78%) | 1,965 (48.51%) | 115 (50.22%) |
|     Mid-Turbinate Nasal Swab | 4,893 (42.05%) | 2,077 (51.30%) | 111 (48.48%) |
|     Other | 136 (1.17%) | 7 (0.17%) | 3 (1.30%) |
|   NAAT Platform | - | - | - |
|     PerkinElmer-Based RT-qPCR | 7,004 (60.19%) | 2,798 (69.10%) | 157 (68.56%) |
|     Lab-Developed RT-qPCR | 2,418 (20.78%) | 610 (15.07%) | 44 (19.21%) |
|     Hologic Panther | 1,219 (10.48%) | 353 (8.72%) | 25 (10.92%) |
|     Cepheid GeneXpert | 573 (4.92%) | 147 (3.63%) | 1 (0.44%) |
|     Roche Liat | 320 (2.75%) | 97 (2.40%) | 0 (0.00%) |
|     Genmark Eplex | 102 (0.88%) | 44 (1.09%) | 2 (0.87%) |
|   RT-qPCR Genotype | - | - | - |
|     L452, E484, N501 | - | 2,308 (57.00%) | 120 (52.40%) |
|     L452R, E484, N501 | - | 1,567 (38.70%) | 70 (30.57%) |
|     L452, E484K, N501 | - | 22 (0.54%) | 14 (6.11%) |
|     L452, E484, N501Y | - | 34 (0.84%) | 22 (9.61%) |
|     L452, E484K, N501Y | - | 3 (0.07%) | 3 (1.30%) |
|     Unable to Genotype[a] | - | 115 (2.84%) | 0 (0.00%) |

NAAT, nucleic acid amplification test; WGS, whole genome next-generation sequencing
[a] Low viral load, amplification failure, or reaction set-up failure despite repeat.

461 **Table 2.** Genotyping RT-qPCR Validation Against Whole-Genome Next-Generation Sequencing
462

| RT-qPCR | Whole-Genome Next-Generation Sequencing | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| | L452R | | E484K | | N501Y | |
| | Detected | Not Detected | Detected | Not Detected | Detected | Not Detected |
| **Detected** | 67 | 3[a] | 17 | 0 | 25 | 0 |
| **Not Detected** | 0 | 159 | 0 | 212 | 0 | 204 |
| **PPA (95% CI)**[b] | 100% (95-100%) | - | 100% (80-100%) | - | 100% (86-100%) | - |
| **NPA (95% CI)**[b] | - | 98% (95-99%) | - | 100% (98-100%) | - | 100% (98-100%) |

CI, confidence interval; PPA, positive percent agreement; NPA, negative percent agreement.
[a] Three specimens positive for L452R by RT-qPCR but negative for L452R by sequencing. Further characterization of these samples provided in results.
[b] RT-qPCR relative to next-generation sequencing.

464 **Table 3.** PANGO Lineage Distribution of Screen-Detected Variants by RT-qPCR
465

| PANGO Lineage | RT-qPCR Genotype | | | | |
|---|---|---|---|---|---|
| | L452R, E484, N501 | L452, E484K, N501 | L452, E484, N501Y | L452, E484K, N501Y | L452, E484, N501 |
| B.1 | 2 (3) | 2 (14) | 1 (5) | 0 (0) | 14 (12) |
| B.1.1 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (2) |
| B.1.1.174 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (1) |
| B.1.1.222 | 1 (1)[a] | 0 (0) | 0 (0) | 0 (0) | 1 (1) |
| B.1.1.228 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (1) |
| P.2[b] | 0 (0) | 11 (79) | 0 (0) | 0 (0) | 0 (0) |
| B.1.1.291 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (1) |
| B.1.1.368 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (2) |
| B.1.1.416 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3 (3) |
| B.1.1.432 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (1) |
| B.1.1.517 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (1) |
| B.1.1.519 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 8 (7) |
| B.1.1.7[c] | 0 (0) | 0 (0) | 17 (77) | 0 (0) | 0 (0) |
| B.1.139 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (2) |
| B.1.2 | 1 (1)[a] | 0 (0) | 3 (14) | 0 (0) | 41 (34) |
| B.1.232 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 5 (4) |
| B.1.234 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3 (3) |
| B.1.239 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (1) |
| B.1.240 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3 (3) |
| B.1.243 | 1 (1)[a] | 0 (0) | 0 (0) | 0 (0) | 6 (5) |
| B.1.265 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (1) |
| B.1.311 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 6 (5) |
| B.1.323 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (1) |
| B.1.351[c] | 0 (0) | 0 (0) | 0 (0) | 3 (100) | 0 (0) |
| B.1.361 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (1) |
| B.1.369 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (2) |
| B.1.375 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (2) |
| B.1.427[c] | 42 (60) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| B.1.429[c] | 23 (33) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| B.1.453 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (1) |
| B.1.480 | 0 (0) | 0 (0) | 1 (5) | 0 (0) | 0 (0) |
| B.1.526[b] | 0 (0) | 1 (7) | 0 (0) | 0 (0) | 0 (0) |
| B.1.561 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 4 (3) |
| B.1.565 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (1) |
| B.1.568 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (1) |
| B.1.577 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (1) |
| B.1.596 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (2) |
| B.1.599 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (1) |
| **Total** | **70** | **14** | **22** | **3** | **120** |

Data presented as n (column %)
[a] Three specimens positive for L452R by RT-qPCR but negative for L452R by next-generation sequencing.
[b] CDC-classified variants of interest
[c] CDC-classified variants of concern

467 **Table 4.** Local Epidemiologic Emergence of L452R
468

| Week of Year, 2020-2021 | Total New Infections Genotyped[a] | L452R Infections |
|---|---|---|
| Weeks 49-52: 2020-12-01 to 2020-12-31[b] | 476 | 118 (24.8%) |
| Week 1: 2021-01-01 | 905 | 300 (33.1%) |
| Week 2: 2021-01-08 | 888 | 330 (37.2%) |
| Week 3: 2021-01-15 | 598 | 267 (44.6%) |
| Week 4: 2021-01-22 | 329 | 141 (42.9%) |
| Week 5: 2021-01-29 | 265 | 145 (54.7%) |
| Week 6: 2021-02-05 | 199 | 102 (51.3%) |
| Week 7: 2021-02-12 | 120 | 70 (58.3%) |
| Week 8: 2021-02-19 | 106 | 64 (60.4%) |
| Week 9: 2021-02-26 | 48 | 30 (62.5%) |
| **Total** | 3,934 | 1,567 (39.8%) |

[a] Confirmed by nucleic acid amplification testing, with diagnosis date assigned by first positive test date.
[b] Grouped due to fewer tested specimens in early December 2020.
[c] Proportion of cases in each week positive for L452R.

    **FIGURE LEGENDS**

**Figure 1.** Flow chart of specimens sent for nucleic acid amplification tests (NAAT) during the study period

and number of specimens ultimately genotyped by multiplex RT-qPCR. *Predominantly specimens with

insufficient material, low viral load ($C_t$>30, RLU<1,100) or positive specimens in December prior to

universal institution-wide genotyping.

**Figure 2.** Nextclade phylogenetic tree of 2,130 SARS-CoV-2 genomes, including 225 of the 229

sequenced genomes from this study, and 1,905 genomes from the Nextstrain global reference tree (left

panel). There were 3 sequenced genomes excluded due to discordance between PCR and sequencing,

and 1 genome excluded due to insufficient quality to assign a clade. The 225 included genomes are

colored by RT-qPCR genotyping result, with each circle representing a sequenced genome. Branch

length corresponds to nucleotide divergence. Arrowheads point to mutations identified either sporadically,

or in rare lineages. Isolates with N501Y mutations predominantly belong to clade 20I/501Y.V1 and

lineage B.1.1.7, though sporadic mutations are noted in clade 20G lineage B.1.2 (top three green

arrowheads) and clade 20A lineage B.1.480 (bottom green arrowhead). In addition to the clade 20B

lineage P.2 variant of concern, E484K RT-qPCR also identified a clade 20C lineage B.1.526 variant of

interest (top two yellow arrowheads), as well as a clade 20A proposed lineage B.1 (bottom yellow

arrowhead). Isolates with L452R mutation (turquoise) belong predominantly to clade 20C, and lineages

B.1.429 and B.1.427 (right panel). Sporadic L452R mutation was noted within one sample belonging to

clade 20A lineage B.1 (turquoise arrowhead). PANGO lineage names and Nextstrain clade names were

assigned as of April 5, 2021.

**Figure 3.** Nextclade phylogenetic tree from Figure 2 magnified to visualize isolates with E484K mutations

in clade 20B lineage P.2 (left panel), and isolates with combined N501Y+E484K mutations, all of which

belong to clade 20H/501Y.V2 lineage B.1.351 (right panel). They are shown next to their nearest

neighbors from the Nextstrain global reference tree, with branch length corresponding to nucleotide

divergence. PANGO lineage names and Nextstrain clade names were assigned as of April 5, 2021.

**Figure 4.** Local epidemiologic emergence of L452R mutations in our genotyped population of 3,934 from

December 2020 to March 2021. Bar plot and left y-axis represent number of new unique genotyped

infections by week grouped by RT-qPCR-defined genotype. Scatter plot and right y-axis represents

proportion of new unique genotyped infections with L452R genotype, with 95% Clopper-Pearson

confidence interval.

Figure 2, page 26